Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
AveXis (AVXS) Ramps 11% on Bullish Analyst Call, $100 PT
-
AveXis (AVXS) PT Raised to $100 at Chardan Capital Markets
-
La Jolla Pharma (LJPC) a Top Pick at Chardan Capital Markets Into Data
-
PlacementTracker Publishes 2016 Private Placement Market League Tables
-
NICE Systems (NICE): Raising PT After Acquisition Closes - Chardan
-
Alnylam Pharmaceuticals (ALNY) PT Raised 41% at Chardan Capital Markets to $97
-
Medicines Co. (MDCO): Top Pick for 2017 - Chardan
-
Chardan Capital Markets Starts Benefitfocus (BNFT) at Buy, $36 PT
-
Chardan Capital Weighs in on 22nd Century Group (XXII) as FDA Responds to MRTP Application
-
Microbot Medical (MBOT) to Sell 700K Shares for $3.5M in Direct Offering
-
Microbot Medical Inc. Announces $3.5 Million Registered Direct Offering
-
Social Reality (SRAX) Announces $4M Direct Offering
-
Social Reality Announces Offering for $4 Million
-
Spinraza Label Suggests AveXis (AVXS) AVXS-101 Should Be The Superior Product - Chardan Capital Markets
-
GlobalStar (GSAT): FCC Approves TLPS - Chardan Capital Markets
-
Northwest Biotherapeutics (NWBO) to Sell 28.6M Shares at $0.35/Share
-
NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $10.0 MILLION WITH INSTITUTIONAL INVESTORS
-
Chardan Capital Markets Upgrades Clovis Oncology (CLVS) to Neutral
-
Origo Acquisition Corporation and Aina Le’a, Inc. Agree to Business Combination
-
Chardan Capital Markets Downgrades iPass Inc. (IPAS) to Neutral
-
Chardan Capital Markets Upgrades Profire Energy (PFIE) to Buy
-
Chardan Capital Markets Downgrades Arbutus Biopharma (ABUS) to Neutral; Safety Risk Overwhelms Promising Efficacy
-
Chardan Capital Markets Starts HealthEquity, Inc (HQY) at Buy
-
Pre-Open Stock Movers 12/12: (AKAO) (AIQ) (CSOD) Higher; (OPHT) (ALXN) (VIAB) Lower (more...)
-
PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial
-
Regeneron (REGN) Gains Early on Ophthotech Wet AMD Failure
-
Chardan Capital Markets Downgrades Ophthotech Corp (OPHT) to Neutral
-
Chardan Capital Markets Upgrades Regeneron Pharma (REGN) to Neutral
-
Palatin Technologies Closes on $16.5 Million Financing
-
Chardan Capital Markets Reiterates Buy on Eyegate Pharma (EYEG) Following Study Results
-
Chardan Capital Markets Reiterates Buy on Vuzix Corp. (VUZI)
-
Chardan Capital Markets Positive on Alnylam (ALNY) as ASH Data Reinforces Potential for RNAi Across Hemophilia and AIP
-
Vuzix Announces Closing of $14,500,000 Common Stock Offering
-
VBL Therapeutics (VBLT) Reports $20M at the Market Offering of Ordinary Shares
-
Palatin Technologies (PTN) Prices $16.5M Common Stock, Warrants Offering
-
Palatin Technologies Announces Pricing of Public Offering of Common Stock and Warrants
-
Palatin Technologies (PTN) Confirms Proposed Offering of Common Stock and Warrants
-
Palatin Technologies Announces Proposed Public Offering of Common Stock and Warrants
-
Notable Analyst Rating Changes 11/30: (UNH) (CE) (GS) Upgraded; (GRA) (FCX) (DLTH) Downgraded
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $89 at Chardan Capital Markets Following Arrowhead's RNAi Program Discontinuations
-
Chardan Capital Markets Starts WageWorks (WAGE) at Buy
-
Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Buy Amid Arrowhead Hepatitis B Program Discontinuations
-
Chardan Capital Markets Downgrades Arrowhead Research (ARWR) to Neutral on EX-1 RNAi Program Discontinuations
-
Vuzix Corp. (VUZI) to Offer 2M Shares of Common Stock for Proceeds of $14.5M
-
Vuzix Announces $14,500,000 Common Stock Offering
-
Chardan Capital Markets Raises Price Target on Amicus Therapeutics (FOLD); Reiterates Buy
-
Chardan Capital Markets Remains Bullish on Vuzix Corp. (VUZI) as Intel Steps Back Relationship
-
Notable Analyst Rating Changes 11/16: (DIS) (FOSL) (PAAS) Upgraded; (NOK) (WDR) (NE) Downgraded
-
Chardan Capital Markets Starts Teladoc (TDOC) at Buy; Sees 40% Upside
-
uniQure (QURE) PT Cut to $12 at Chardan Capital Markets; 'Buy' Maintained on Simplification

